Want to see IN:GUFICBIO full AI Analyst Report?
GUFICBIO Stock Chart & Stats
₹378.25
₹3.40(0.90%)
At close: 4:00 PM EDT
₹378.25
₹3.40(0.90%)
Day’s Range― - ―
52-Week Range₹267.50 - ₹447.85
Previous CloseN/A
Volume48.22K
Average Volume (3M)2.36K
Market Cap
₹40.92B
Enterprise Value₹30.82K
Total Cash (Recent Filing)₹621.86M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)56.3
Beta0.68
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)7.32
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-5.32
Price to Book (P/B)4.13
Price to Sales (P/S)2.91
P/FCF Ratio-152.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Re-accelerating Revenue GrowthThe return to revenue growth indicates renewed demand for the company’s pharmaceutical portfolio. Sustained sales expansion can improve operating leverage and support investment in formulations, injectables, manufacturing capacity, and distribution.
Established Pharmaceutical Manufacturing PlatformA diversified formulation portfolio and injectable focus provide a platform for serving domestic and international markets. Manufacturing capabilities can support recurring product sales, regulatory expansion, and broader customer or partner relationships.
Manageable LeverageModerate leverage and improving debt-to-equity provide some balance-sheet resilience while the company expands its asset base. This gives Gufic more flexibility than a heavily indebted peer if operating performance stabilizes.
Bears Say
Weak Cash GenerationThe sharp decline in operating cash flow and negative free cash flow indicate poor earnings-to-cash conversion. Persistent working-capital or investment pressures could limit funding for growth, increase reliance on borrowing, and weaken financial flexibility.
Margin And Earnings PressureLower net margins and declining net income despite higher sales suggest weaker earnings conversion. If pricing pressure, product mix, or costs remain unfavorable, profitability may stay constrained and reduce the benefits of future revenue growth.
Declining Returns And Financial FlexibilityFalling returns on equity indicate that the growing capital base is producing less profit than in earlier years. Combined with higher debt than FY2021–FY2022, this could restrict flexibility if cash generation remains volatile.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹447.85 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹40.92B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is Nov 12, 2026 which is in 75 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on Aug 14, 2026. The company reported ₹2.225 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.02%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹2.225 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.285%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―